CEACAM5 and neoplasm: Imaging remains normal with no evidence of recurrence or progression, and tumor markers have remained normal, with CEA at 2.85 ng/ml and CYFRA21–1 at 2.52 ng/ml on April 22, 2024 (Figure 2A).